2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Key Takeaways
Pharmaceutical giants Pfizer (PFE -0. Conversely, 06%) and Novo Nordisk (NVO 1 (this bears monitoring). Furthermore, 04%) have lagged the market over the past year, although Pfizer's poor performance dates...
Article Overview
Quick insights and key information
5 min read
Estimated completion
investment
Article classification
July 21, 2025
08:15 AM
The Motley Fool
Original publisher
Pharmaceutical giants Pfizer (PFE -0
Conversely, 06%) and Novo Nordisk (NVO 1 (this bears monitoring)
Furthermore, 04%) have lagged the market over the past year, although Pfizer's poor performance dates back much further (an important development)
Though these companies have encountered challenges, there are good reasons to be bullish on their long-term spects
On the other hand, Pfizer could become an even bigger player in the oncology market (the largest therapeutic area in the industry by sales) over the next decade, while Novo Nordisk will be a major player in diabetes and the fast-growing weight management space
On the other hand, Both could duce excellent results along the way
However, Here's the rundown
Image source: Getty Images
Additionally, Pfizer Pfizer's financial results haven't been great in recent years
However, To make matters worse, the company will face important patent cliffs by the end of the decade
One of them will be for Eliquis, an anticoagulant that is still one of its best-selling medicines
However, Pfizer has prepared for that eventuality
The company made several acquisitions and licensing deals that significantly boosted its pipeline, especially in oncology
Pfizer spent $43 billion to acquire Seagen, a smaller cancer specialist whose lineup and pipeline were impressive for a company of its size
With the financial and strategic backing of the larger company, it should yield even more key apvals in the field in the coming years
In contrast, Pfizer also recently made an up-front payment of $1, amid market uncertainty
In contrast, 25 billion to China-based 3SBio for the rights to SSGJ-707, an investigational bispecific antibody, a portion of the oncology market that's gaining traction these days (this bears monitoring), considering recent developments. 3SBio will be eligible for commercial and regulatory milestone payments of up to $4. 8 billion, not including royalties
Furthermore, These moves should eventually pay off for Pfizer and strengthen its position in oncology
What the data shows is drugmaker plans to have eight blockbuster cancer medicines on the market by 2030, up from its current five, while doubling its reach from the current 1 million patients it serves
Of course, Pfizer isn't just a cancer play, in this volatile climate
The company's extensive pipeline should enable it to launch ducts in other areas and ultimately get back on track
On the other hand, Additionally, While its s have been lagging the market significantly, that could change in the next decade as financial results rebound thanks to its innovative efforts
Pfizer's s look especially attractive when considering its valuation
Its forward price-to-earnings (P/E) ratio is 8. 7, much lower than the healthcare sector's 15
From their current levels, Pfizer's s could go on to generate excellent returns through 2035
Additionally, Novo Nordisk Novo Nordisk pioneered the market for weight management medicines
However, Eli Lilly seems to have taken the lead in that field, at least for now
Novo Nordisk has faced some clinical setbacks, leading to a poor performance over the trailing-12-month period, in today's financial world
Can the company rebound and perform well in the next decade
On the other hand, In my view, it can, and the market may be significantly undervaluing its potential
Its sales of Wegovy, one of the top-selling anti-obesity medications, continue to grow rapidly
Moreover, At the same time, Novo Nordisk recently requested apval from the U (fascinating analysis)
Additionally, Food and Drug Administration for oral semaglutide (the active ingredient in Wegovy)
That's good for patients who want a non-injected option, and helps counter Lilly's up-and-coming oral GLP-1 medicine, orforglin
Elsewhere, Novo Nordisk recently started phase 3 studies for amycretin, a next-gen weight loss candidate
Meanwhile, Amycretin is being investigated in both oral and subcutaneous formulations, and both are currently in late-stage clinical trials (something worth watching)
The company also enhanced its pipeline through licensing deals, including one with United Bionology, a subsidiary of the China-based company United Laboratories International Holdings, for UBT251, in light of current trends
This potential anti-obesity medicine mimics the actions of three gut hormones: GLP-1, GIP, and glucagon
The transaction cost Novo Nordisk an up-front payment of $200 million and up to $1
Meanwhile, 8 billion in milestone payments
Additionally, Thanks to all these developments, Novo Nordisk should remain a leader in weight management in the next decade
Even though competition is mounting, no drugmaker not named Eli Lilly has a lineup or a pipeline as deep as Novo Nordisk's
Additionally, Furthermore, the Denmark-based pharmaceutical leader will also continue to dominate the diabetes market, as it has done for decades, in light of current trends
Novo Nordisk generates consistent revenue and earnings that typically grow faster than those of similarly-sized peers, given current economic conditions
In contrast, Yet the stock's forward P/E is 16 (an important development)
On the other hand, 7, which is slightly above the industry average (which is quite significant), in today's financial world
Furthermore, In my view, that's a bargain for a company that generates better-than-average results and has a deep pipeline in a fast-growing area -- not to mention two of the world's top 20 best-selling drugs, in Wegovy and Ozempic (this bears monitoring)
For investors willing to stay the course, Novo Nordisk's future still looks incredibly bright
Sper Junior Bakiny has positions in Eli Lilly and Novo Nordisk
Additionally, At the same time, The Motley Fool has positions in and recommends Pfizer, in today's financial world
However, The Motley Fool recommends Novo Nordisk (this bears monitoring), given current economic conditions
The Motley Fool has a disclosure policy, given current economic conditions.
Related Articles
More insights from FinancialBooklet